# Growth Hormone Axis Research Peptides, Without the Fountain-of-Youth Story > The Peptide Brand — Growth Hormone Axis Research Peptides — Growth Hormone Axis research peptides explained through the somatopause question: cited, independent reviews of sermorelin, tesamorelin, CJC-1295, and ipamorelin. **FIELD NOTE 01 / THE SOMATOPAUSE QUESTION** Four signals, two receptor routes, and one disciplined question: what does the literature actually show about age-related GH decline? ### [Sermorelin](/sermorelin) ![Sermorelin research illustration](images/sermorelin.webp) The active GHRH fragment and this desk’s clearest lens on pituitary responsiveness with age. ### [Tesamorelin](/tesamorelin) ![Tesamorelin research illustration](images/tesamorelin.webp) A stabilized GHRH analogue with the group’s strongest indication-specific human evidence. ### [CJC-1295](/cjc-1295) ![CJC-1295 research illustration](images/cjc-1295.webp) A duration experiment: prolonged GH/IGF-1 pharmacology, limited outcomes evidence. ### [Ipamorelin](/ipamorelin) ![Ipamorelin research illustration](images/ipamorelin.webp) The ghrelin-receptor outlier, with sparse human outcomes evidence and prominent preclinical work. ## Start with the signal, not the slogan Growth hormone, or GH, is a chemical messenger released by the pituitary gland in pulses. It helps coordinate growth, tissue turnover, metabolism, and the production of insulin-like growth factor 1, usually shortened to IGF-1. Those pulses tend to become smaller with age—a pattern sometimes called **somatopause**—but that descriptive label is not itself a disease diagnosis. Older-adult research confirms that GH and IGF-1 can sit below levels seen in younger comparison groups [7]. The four peptides on this desk probe that signaling system from two directions. Sermorelin, tesamorelin, and CJC-1295 imitate growth hormone-releasing hormone, the brain’s upstream instruction to the pituitary. Ipamorelin instead activates the ghrelin receptor, another route to a GH pulse. That distinction is interesting; it is not a promise of restored youth. Evidence ranges from an approved, narrow clinical use for tesamorelin [9] to early pharmacology and animal work. This digest follows the studies, marks the gaps, and keeps age-related curiosity separate from medical claims. ## Somatopause is a research frame, not a verdict “Somatopause” is shorthand for the gradual weakening of the GH/IGF-1 signal observed across aging. The term can sound like a clean endocrine event, yet the biology is less tidy. GH arrives in pulses rather than as a steady stream, sleep and metabolic state shape those pulses, and a single measurement does not capture the whole rhythm. In a small study of older men, repeated GHRH(1-29) raised daily GH and IGF-1 measures toward those of younger men over the study window [7]. That finding shows the aging pituitary can still respond to an upstream signal. It does not establish an anti-aging treatment. That boundary matters because interest often races ahead of outcomes. An editorial examining growth hormone secretagogues for the effects of aging concluded that the evidence did not justify that use [3]. The current research question is therefore narrower and more useful: what happens to measured GH-axis signals, body composition, cognition, metabolism, or safety markers when a particular pathway is stimulated in a defined population? A modern review places GHRH analogues across both experimental and therapeutic settings, while emphasizing that molecule design, target population, and duration change the interpretation [1]. ## What are research peptides? Peptides are short chains of amino acids, the same building blocks used to make larger proteins. Some act as signals because their shapes fit specific receptors. A research peptide may be used as a laboratory probe, an investigational drug candidate, a former medicine, or an approved prescription medicine for a narrow indication. Those categories are not interchangeable. The GHRH analogues here imitate part of an endogenous signal. Sermorelin is based on the active amino-terminal fragment of GHRH. Tesamorelin modifies the longer hormone to resist rapid breakdown. CJC-1295 uses stabilizing substitutions and, in its DAC form, an albumin-binding design intended to prolong exposure. Ipamorelin is different: it is a small ghrelin-receptor agonist, not a GHRH analogue. Calling all four “GH peptides” may be convenient, but it conceals meaningful differences in receptor, persistence, evidence, and regulatory standing. The word *research* also does not certify purity or safety. One analytical paper identified CJC-1295 in an unknown preparation obtained in an anti-doping context [13]. That is a reminder that a compound’s published pharmacology says nothing about the identity of unverified material. This site is an independent literature digest, not a source, clinic, or protocol guide. ## Four compounds, four different questions [**Sermorelin**](/sermorelin) is the lead because it makes the aging frame easiest to understand: it is a short GHRH fragment that asks whether the pituitary can answer its own upstream language. Human studies document GH release and older-adult axis responses, while the anti-aging evidence remains insufficient [6][7][3]. [**Tesamorelin**](/tesamorelin) carries the most developed clinical evidence of this group, but in a specific setting: excess abdominal fat associated with HIV lipodystrophy. Trials and pooled analyses report visceral and hepatic fat outcomes in that population [8][10][12]. That does not turn it into a general “belly-fat peptide.” [**CJC-1295**](/cjc-1295) is a long-acting GHRH analogue whose early human studies focused on pharmacology: how long GH and IGF-1 stayed elevated and whether pulsatile secretion persisted [15][16]. Its evidence base is small and does not establish anti-aging outcomes. [**Ipamorelin**](/ipamorelin) approaches the axis through GHS-R1a, the ghrelin receptor. A human postoperative trial missed its primary efficacy endpoint [19], while newer work includes animal models [17]. Read together, the four form a map of mechanisms and evidence maturity—not a ranking of products. The [comparison matrix](/compare) makes those differences explicit. --- The Peptide Brand is an independent field guide to the aging GH axis—curious about every signal, exacting about every caveat, and never a clinic, vendor, or prescription.